The new Alzheimer’s drug Aduhelm could lead to higher Part B premiums for beneficiaries in both Medicare Advantage and fee-for-service, and state and federal spending on Medicaid will likely also rise, according to the Kaiser Family Foundation. It’s difficult to predict how many Alzheimer’s patients will take Aduhelm. Medicare could use a national coverage policy to restrict coverage. That would take time to put in place, and until then, Medicare Advantage plans and the contractors that make regional coverage decisions...